Comparative review of drug–drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer
ZY Xu, JL Li - OncoTargets and therapy, 2019 - Taylor & Francis
The development of small-molecule tyrosine kinase inhibitors (TKIs) that target the
epidermal growth factor receptor (EGFR) has revolutionized the management of non-small …
epidermal growth factor receptor (EGFR) has revolutionized the management of non-small …
Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta …
Purpose Pneumonitis is a significant toxicity of EGFR tyrosine kinase inhibitors (EGFR-TKI)
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
in non-small-cell lung cancer (NSCLC) patients. We studied the incidence of pneumonitis in …
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials
L Shi, J Tang, L Tong, Z Liu - Lung Cancer, 2014 - Elsevier
Objectives Gefitinib and erlotinib are oral epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) widely used in advanced non-small cell lung cancer (NSCLC) …
kinase inhibitors (TKIs) widely used in advanced non-small cell lung cancer (NSCLC) …
[HTML][HTML] EGFR targeted therapy for lung cancer: are we almost there?
G Metro - Translational Lung Cancer Research, 2018 - ncbi.nlm.nih.gov
© Translational lung cancer research. All rights reserved. Transl Lung Cancer Res 2018; 7
(Suppl 2): S142-S145 tlcr. amegroups. com patients assigned to gefitinib than for those …
(Suppl 2): S142-S145 tlcr. amegroups. com patients assigned to gefitinib than for those …
Long‐term safety and survival with gefitinib in select patients with advanced non–small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP)
FR Hirsch, LV Sequist, I Gore, M Mooradian, G Simon… - Cancer, 2018 - Wiley Online Library
BACKGROUND This is the first report of long‐term (> 10 years) safety, tolerability, and
survival data on patients with non–small cell lung cancer (NSCLC) who received treatment …
survival data on patients with non–small cell lung cancer (NSCLC) who received treatment …
[HTML][HTML] Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis
W Zhang, Y Wei, D Yu, J Xu, J Peng - Medicine, 2018 - journals.lww.com
Background: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis …
erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis …
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials
M Burotto, EE Manasanch, J Wilkerson, T Fojo - The oncologist, 2015 - academic.oup.com
Abstract Background. Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …
receptor (EGFR) have been evaluated in patients with metastatic and advanced non-small …
Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung …
T Hirose, K Fujita, S Kusumoto, Y Oki, Y Murata… - Lung Cancer, 2016 - Elsevier
Objectives Gefitinib is a potent epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor and is a key drug for patients with EGFR mutation-positive advanced non-small cell …
inhibitor and is a key drug for patients with EGFR mutation-positive advanced non-small cell …
Effects of Proton Pump Inhibitor Coadministration on the Plasma Concentration of Erlotinib in Patients With Non–Small Cell Lung Cancer
M Ohgami, T Kaburagi, A Kurosawa… - Therapeutic drug …, 2018 - journals.lww.com
Background: Erlotinib is used for treating non–small cell lung cancer (NSCLC). Intestinal
absorption of erlotinib is impaired under gastric pH elevation; therefore, coadministration of …
absorption of erlotinib is impaired under gastric pH elevation; therefore, coadministration of …
Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: a phase 1/2 single-group open-label trial
Importance The combination of erlotinib and bevacizumab as initial treatment of epidermal
growth factor receptor (EGFR [OMIM131550])–mutant lung cancers improves progression …
growth factor receptor (EGFR [OMIM131550])–mutant lung cancers improves progression …